SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27, 2024.

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its common stock.

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET.

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present two posters in classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024.

SAN DIEGO , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. , (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow Healthcare Conference Tuesday, August 13, 2024 , at 2:30 p.m.

SAN DIEGO , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2024 financial results and provided a corporate update.

SAN DIEGO , July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. , (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024 , after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET .

SAN DIEGO , July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. , (NASDAQ: TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024 , at 11:30 a.m. ET .